CTLA4 and non-small cell lung carcinoma: Later on, ipilimumab was approved for the treatment of other malignancies, including renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) [34], malignant pleural mesothelioma, etc. In a similar fashion, another CTLA-4 targeting ICI, namely tremelimumab, was approved by the Food and Drug Administration in combination regimens in the setting of HCC [35] and NSCLC [36].